SULOCTIDIL HYDROCHLORIDE

Details

Stereochemistry	RACEMIC
Molecular Formula	C20H35NOS.ClH
Molecular Weight	374.024
Optical Activity	( + / - )
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.CCCCCCCCN[C@@H](C)[C@H](O)C1=CC=C(SC(C)C)C=C1

InChI

InChIKey=JRJJHIUHSILDOH-ZHXLSBKVSA-N

InChI=1S/C20H35NOS.ClH/c1-5-6-7-8-9-10-15-21-17(4)20(22)18-11-13-19(14-12-18)23-16(2)3;/h11-14,16-17,20-22H,5-10,15H2,1-4H3;1H/t17-,20-;/m0./s1

HIDE SMILES / InChI

Description
Sources: http://onlinelibrary.wiley.com/doi/10.1111/j.1527-3466.1986.tb00494.x/full | https://www.ncbi.nlm.nih.gov/pubmed/2839389

Suloctidil is considered to be calcium antagonist. In addition to its vascular antispasmodic activity, suloctidil affects blood platelets and enhances brain energy metabolism. Suloctidil was being evaluated in many clinical trials for use in dementia and thrombotic disorders. Suloctidil induces hepatotoxicity.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
calcium channel activity 11 Target ID: GO:0005262 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6324812 \| https://www.ncbi.nlm.nih.gov/pubmed/3030204	Blocker 537	0.45 µM [Ki]
platelet aggregation 76 Target ID: GO:0070527 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1265708 \| https://www.ncbi.nlm.nih.gov/pubmed/3023210	Inhibitor 8297
Sphingomyelin phosphodiesterase 7 Target ID: CHEMBL2760 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18027916	Inhibitor 8297

Conditions

Condition	Modality	Highest Phase	Product
Stroke 144 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2988158	Primary	Withdrawn	Unknown Approved Use Unknown
Dementia 27 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14591143	Primary	Withdrawn	Unknown Approved Use Unknown
Candida infections 20 Sources: https://www.ncbi.nlm.nih.gov/pubmed/29050256	Curative	Preclinical	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Combining chemical genomics screens in yeast to reveal spectrum of effects of chemical inhibition of sphingolipid biosynthesis.	2009 Jan 14	19144191
A repurposing approach identifies off-patent drugs with fungicidal cryptococcal activity, a common structural chemotype, and pharmacological properties relevant to the treatment of cryptococcosis.	2013 Feb	23243064

Patents

Sample Use Guides

In Vivo Use Guide

200 mg t.i.d.

Route of Administration: Oral

In Vitro Use Guide

Suloctidil (10 microM) stimulated the release of prostacyclin (PGI2) from the rabbit aorta, the dog vena cava and the dog portal vein, in vitro.

Name

Type

Language

SULOCTIDIL HYDROCHLORIDE

Common Name

English

BENZENEMETHANOL, 4-((1-METHYLETHYL)THIO)-.ALPHA.-(1-(OCTYLAMINO)ETHYL)-, HYDROCHLORIDE, (R*,S*)-

Systematic Name

English

Code System Code Type Description

PUBCHEM

44153242